Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bayer Aktiengesellschaft (BAYRY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bayer Aktiengesellschaft is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy).Over the past three months, the Zacks Consensus Estimate for BAYRY's full-year earnings has moved 0.6% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.Based on the latest available data, BAYRY has gained about 37.5% so far this year. At the same time, Medical stocks have gained an average of 6.8%. This means that Bayer Aktiengesellschaft is performing better than its sector in terms of year-to-date returns.Another Medical stock, which has outperformed the sector so far this year, is AbbVie (ABBV). The stock has returned 18.6% year-to-date.Over the past three months, AbbVie's consensus EPS estimate for the current year has increased 1%. The stock currently has a Zacks Rank #2 (Buy).Breaking things down more, Bayer Aktiengesellschaft is a member of the Large Cap Pharmaceuticals industry, which includes 12 individual companies and currently sits at #60 in the Zacks Industry Rank. This group has gained an average of 11.9% so far this year, so BAYRY is performing better in this area. AbbVie is also part of the same industry.Going forward, investors interested in Medical stocks should continue to pay close attention to Bayer Aktiengesellschaft and AbbVie as they could maintain their solid performance.Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks